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Multidisciplinary first-day consultation
accelerates diagnostic procedures and
throughput times of patients in a head-
and-neck cancer care pathway, a mixed
method study
Lidia S. van Huizen1,2* , Pieter U. Dijkstra1,3, Bernard F. A. M. van der Laan4, Harry Reintsema1, Kees T. B. Ahaus5,
Hendrik P. Bijl6 and Jan L. N. Roodenburg1
Abstract
Background: Head and neck cancers are fast growing tumours that are complex to diagnose and treat. Multidisciplinary
input into organization and logistics is critical to start treatment without delay. A multidisciplinary first-day consultation
(MFDC) was introduced to reduce throughput times for patients suffering from head and neck cancer in the care
pathway. In this mixed method study we evaluated the effects of introducing the MFDC on throughput times, number of
patient hospital visits and compliance to the Dutch standard to start treatment within 30 calendar-days.
Methods: Data regarding ‘days needed for referral’, ‘days needed for diagnostic procedures’, ‘days to start first treatment’,
and ‘number of hospital visits’ (process indicators) were retrieved from the medical records and analysed before and after
implementation of the MFDC (before implementation: 2007 (n= 21), and after 2008 (n = 20), 2010 (n= 24) and 2013
(n = 24)). We used semi-structured interviews with medical specialists to explore a sample of outliers.
Results: Comparing 2007 and 2008 data (before and after MFDC implementation), days needed for diagnostic
procedures and to start first treatment reduced with 8 days, the number of hospital visits reduced with 1.5 visit on
average. The percentage of new patients treated within the Dutch standard of 30 calendar-days after intake increased
from 52 to 83%.
The reduction in days needed for diagnostic procedures was sustainable. Days needed to start treatment increased in
2013. Semi-structured interviews revealed that this delay could be attributed to new treatment modalities, patients
needed more time to carefully consider their treatment options or professionals needed extra preparation time for
organisation of more complex treatment due to early communication on diagnostic procedures to be performed.
Conclusions: A MFDC is efficient and benefits patients. We showed that the MFDC implementation in the care
pathway had a positive effect on efficiency in the care pathway. As a consequence, the extra efforts of four specialist
disciplines, a nurse practitioner, and a coordinating nurse seeing the patient together during intake, were justified. Start
treatment times increased as a result of new treatment modalities that needed more time for preparation.
Keywords: First-day consultation, Oncology, Management care pathways, Critical pathways (MeSH), Process indicators,
Mixed method study, Head and neck cancer
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Background
The tumours in the head or neck region (nasal cavity, si-
nuses, lips, mouth, salivary glands, throat, or larynx) are fast
growing tumours. This means that a long interval between
the moment of referral and the start of the primary treat-
ment (surgery, radiotherapy and/or chemotherapy) can lead
to upstaging of the tumour with less chance on cure [1].
Because of the complexity of the diagnostic procedures and
therapeutic modalities, head and neck cancer care is cen-
tralized in special multidisciplinary head and neck cancer
centres [2]. Although the patient’s prognosis is determined
by tumour stage, throughput time, defined as ‘day from first
visit to day of start of treatment’ should be kept as short
as possible [3, 4]. According to the Dutch Cooperative
Head & Neck Group [5] treatment should start within
30 calendar-days after intake for 80% of new patients.
Until September 2007, the intake of head and neck pa-
tients at the University Medical Center Groningen
(UMCG) was performed by the Department of Oral and
Maxillofacial Surgery (OMS) and the Department of Ear,
Nose & Throat (ENT), the front offices for the multidis-
ciplinary head and neck centre. On the day of intake, the
specialists or the nurse practitioner of the gate depart-
ments planned the diagnostic procedures, and two
weeks after that, the diagnosis and treatment plan were
discussed in the multidisciplinary meeting. In the mean-
time the involved supportive paramedical specialists,
such as the dental team (special care dentist, oral hy-
gienist), speech therapists, dieticians, and medical social
workers, were consulted prior to the multidisciplinary
meeting. This meeting was the first opportunity for a
multidisciplinary discussion in the care pathway about
treatment, based on written history, physical examin-
ation, laboratory data, and imaging. The patient was not
present during the meeting.
In the Netherlands, the number of head and neck can-
cer cases increased between 1989 and 2016 [6] from
1934 to 2995 cases which is an increase of 55%. The
highest increase is seen for patients over 75 years with
88% followed by the age group 60–74 years with 80%
(Table 1). This increase and limited resources were
reasons to improve the efficiency of diagnostics and
treatment for patients and because the performance of
the centre on throughput time was poor in 2007 (only
52% of patients started their treatment within the 30-day
standard), the centre decided to implement a multidis-
ciplinary first-day consultation (MFDC) to reduce the
time to start treatment.
Whilst care pathways are organized with multidiscip-
linary patient meetings (MPM), but as evidence based
guidelines are accepted to organize care, the added value
of each MPM still should be proven [7]. Brunner et al.
support this view in 2015 by explaining that the last
30 years multidisciplinary team meetings have become
an essential component of tertiary-level decision-making
in the treatment of malignancy [8]. It seems self-evident
that the variety of specialist team members with their
combined knowledge and expertise improve decision
making and therefore a MPM is often described in
guidelines as a structure indicator.
The research question is: what are the effects of the
MFDC implementation on efficiency of the care path-
way, measured as process indicators throughput times
(referral, diagnostic procedures and start treatment) and
number of hospital visits (Fig. 1).
Methods
The MFDC was introduced in 2007 in the head and
neck cancer care pathway using an ‘8-step method’
[9, 10]. The method compares the current with the
desired situation to formulate improvement measures
and realise sustainable change.
While the intake in the morning by the department
of OMS and the department of ENT remained the
same, the MFDC in the afternoon of the same day
served as an extra effort among the two front office
departments OMS and ENT and the department
Radiotherapy. The four contributing specialities are
ENT, Radiotherapy, OMS and the Special Dental Care.
Special Dental Care is a sub-department within the
Department OMS. The MFDC aims to provide a prelimin-
ary diagnostic plan, with multidisciplinary agreement,
stating the diagnostic procedures to be performed, so in-
take for treatment modalities could start as soon as pos-
sible. The patient is informed on his or her diagnostic plan
at the end of the day.
We applied a mixed method study [11, 12] combining
statistical results and interviews. Firstly in search for
process indicators for care pathway management we
evaluated throughput times and number of hospital
visits, secondly we performed semi-structured inter-
views of involved specialists of core departments to ex-
plore outliers in throughput times until data-saturation
was reached.
Table 1 Incidence rates Head & Neck Cancer in the Netherlands
Period Number of cases per age category Total Dutch
population0–14 15–29 30–44 45–59 60–74 75+
1989 3 17 139 546 852 377 1934 14,805,240
1990 1 17 144 606 900 409 2077 14,892,574
2007 2 20 132 804 1109 587 2654 16,357,992
2008 5 26 133 849 1291 575 2879 16,405,399
2010 2 17 120 814 1326 596 2875 16,574,989
2013 0 25 91 776 1421 644 2957 16,779,575
2016 0 13 72 669 1531 710 2995 16,979,120
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Patients
The MFDC started in August 2007.
Four data sets were extracted, one data set of consecutive
patients who were referred at least four months before the
start of the MFDC (from April 2007 backwards), one data
set of consecutive patients referred four months after the
implementation of the MFDC (from January 2008 on-
wards) to compare immediate effects of MFDC. Two more
datasets were extracted to analyse sustainability of the im-
provement over the five years after the implementation of
the MFDC, one set of consecutive patients from January
2010 onwards and one set from January 2013 onwards.
Data of patients were included if they were 18 years of
age and older, who had been curatively treated for a pri-
mary carcinoma of lips, oral cavity, oropharynx, nasophar-
ynx, hypopharynx, or larynx (ICD(O) coding C00 through
C14, C30 through C32) [13]. Data were excluded if patients
were treated for an unknown primary tumour (C80), a
second primary tumour in the head or neck region or if a
recurrent or residual tumour was diagnosed.
Process indicators and study design
The Dutch Cooperative Head & Neck Group devel-
oped the standard of ‘80% of the patients with a head
and neck tumour start their primary treatment within
30 calendar-days from day of intake’, together with
maximum throughput time for access to consultation
and start treatment [2, 4]. For the evaluation of the ef-
fects of the implementation of the MFDC, the process
indicators throughput times and number of hospital
visits were used [1, 14–16]. We distinguished three
different throughput times: the time to gain access to
the first oncology consultation (access first consult-
ation); the time to finish the diagnostic procedures, in-
cluding the treatment plan (diagnostic procedures);
and the time to start the first treatment (start first
treatment). The throughput times ‘access first consult-
ation’, ‘diagnostic procedures’ and ‘start first treatment’
were measured from the day the patients had their
first oncology consultation in either one of the front
offices of the centre. In the pre and post intervention
situation in the centre, the consultation or intake was
done once a week, independent of the number of pa-
tients referred (Fig. 1).
The first author registered the relevant data in a clin-
ical registration form from electronic and written med-





























OMS = Oral and Maxillofacial Surgery
ENT = Ear, Nose & Throat
RT = Radiotherapy
MO = Medical Oncology
MFDC = Multidisciplinary First Day Consultation
MPM = Multidisciplinary Patient Meeting


















Fig. 1 Care Pathway Head & Neck Oncology and throughput time definition. Legend Fig. 1. The care pathway consists of diverse personnel of four
core departments (ENT, OMS, MO, and RT). The care pathway sub-processes are called ‘intake - diagnostic procedures – treatment – follow-up’. There
are four treatment modalities: surgery, primary radiation, chemo and chemo-radiation. In the red circle the intervention: the MFDC
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Statistical analysis
Our primary outcome measure was the change in the
throughput time to start the first treatment as a result of
the intervention of implementing the MFDC. Initially the
sample size was set at about 20 patient records in each
period (2007 and 2008) as a starting point to evaluate man-
agement of the care pathway over the years. Based on an
analysis of these samples we would determine the definitive
sample size. However in the analysis significant differences
were found in throughput times hence data acquisition re-
garding 2007 and 2008 was not continued. Additionally to
analyse sustainability of data, records of 24 patients from
2010 and 24 from 2013 were used. Statistical analysis was
performed using SPSS 23.0 for Windows software.
Analysis of variance was applied to outcome vari-
ables throughput time (referral, diagnostic procedures,
start first treatment) and number of hospital visits
(total, from intake to diagnostic procedures complete,
from diagnostic procedures complete to start treat-
ment), ‘age at start treatment’. Because samples were
small and assumptions were not met, biased corrected
bootstrapping (2000 samples) was applied [17]. The
exact chi-square test was used to analyse differences
in descriptive variables between the groups, regarding
gender, tumour localization and tumour size, and
compliance to the Dutch 30-day standard.
In all analyses, statistical significance was set at the
5% level.
Qualitative analysis
Semi-structured interviews were used to explore reasons
for non-compliance to the Dutch 30-day standard for
starting the first treatment. Therefore the cutting point
for ‘outliers’ chosen was defined as ‘longer than 37 days
to start treatment’ (years 2008, 2010 and 2013); reflect-
ing non-compliance to the Dutch 30-day standard and a
(patient) delay of one week; for example if the first
opportunity for outpatient clinic was skipped, either by
the patient or for another reason.
We used the outlier cases to start the semi-structured in-
terviews with one representative of each of the four depart-
ments that work together in the care pathway to give
primary treatment (ENT, OMS, Radiotherapy and Medical
Oncology). Prior to the interview the specialists were given
the medical records of the outlier(s) to enhance recalling
the case. Each semi-structured interview with a specialist
started after getting verbal informed consent of the inter-
viewees by providing them with information about the out-
liers. The interviewer (first author) then guided the
interview using a short topic list including ‘cause of the
delay’ and ‘perceived possibilities for change or improve-
ment in logistics or of the care pathway’. The topics were
introduced in a flexible way, and the interviews took the
form of natural conversations.
The interviews were audio recorded and field notes
were taken. Verbal transcripts of the interviews were
made with the transcription program F4. The inter-
views lasted from 25 to 40 min. Quotations, related to
throughput time or number of hospital visits, or im-
provement of the care pathway, were numbered in
chronology of the interview. The first stage of the in-
ductive analysis of interviews involved the last author
and third author, in an open, initial coding procedure
that resulted in a list of codes corresponding closely to
the text fragments extracted from the four interviews.
The codes were placed in a coding tree with major and
minor themes in relation to management of the care
pathway (Table 4) [18]. Any disagreements about the




In total 89 medical records were included in the study:
21 in the ‘pre MFDC group, year 2007’ and 68 in the
‘post MFDC group, year 2008-2010-2013’ (Table 2).
Two-thirds of the groups were men, with a mean age of
66 years. The tumours were located in the oral cavity
(tongue, gums or floor of mouth), the salivary glands,
oropharynx, nasopharynx, hypopharynx, or larynx. The
primary tumour classification ranged from T1 to T4
[20]. We found no significant differences between the
pre MFDC group and the post MFDC group in patient
and tumour characteristics.
Throughput times for the diagnostic procedures and
start treatment decreased significantly, with an average of
eight days, after the implementation of the MFDC (com-
parison between 2007 and 2008) through the extra effort
of the four specialist disciplines while no increase in
personnel capacity was possible in the care pathway. Time
to gain access to the first oncology consultation did not
change significantly (Fig. 2 and Table 3).
The number of hospital visits during the diagnostic phase
reduced significantly with one visit (p < .032) after the im-
plementation of the MFDC (Table 3). Furthermore we ana-
lysed hospital visits during the diagnostic phase and from
diagnosis to start treatment; for 2013 we saw an increase
for hospital visits during the diagnostic procedures and an
increase in the total number of hospital visits (Table 3).
Before implementation of the multidisciplinary first-day
consultation, treatment started for 52% of new patients
within 30 calendar-days after the first consultation. After
implementation of the multidisciplinary first-day con-
sultation, this percentage increased significantly to 83%
(p < .040). This percentage decreased again in 2010 and
2013. In 2013 waiting time to start treatment increased
for all treating modalities, therefore outliers were ana-
lysed. In total, we defined 8 cases (12%) as ‘outlier’.
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Qualitative analysis – Specialist interviews
The specialists spontaneously gave their view on the
agreements in the care pathway and described changes
in guidelines, such as new treating modalities that may
have increased throughput time.
In some cases the different aspects of a quotation was
scored separately (Table 4). The interviews gave in total
76 scores, 37 quotations that were coded with 19 codes.
Quotations appear in the text in italic.
Analysing the interviews we learned that:
– introduction of new cure modalities chemotherapy
and chemo-radiation took more preparation time
and more hospital visits, coded as: ‘Planning
reconstruction costs extra time’.
‘Duration and severity of surgery is not only the
dissection of the tumour, but also the reconstruction
that is discussed in the reconstruction meeting, like an
obturator or a flap.’
‘The treatment date is known [date], but clearly there
were not enough slots in the ‘major surgery planning’
to treat this patient in time.’
– specialists were not aware that throughput times were
lengthening, because information on throughput
times is not easily available in the electronic patient
dossier, coded as: ‘No management information on
throughput times in electronic patient dossier’.
‘The gate specialist department agreed that they were
supposed to keep track of throughput times, although
this agreement was not traceable in writing.’
‘Register more accurately the throughput time when time
to start treatment is longer than the 30-day standard.’
‘BROC (database for oncology registration) is only
meant for basic tumour registration, not for
management information on quality indicators.’
Table 2 Patient and tumour characteristics
Pre-MFDC Post-MFDC Sign.
2007 (n = 21) 2008 (n = 20) 2010 (n = 24) 2013 (n = 24) ANOVA
Age Mean(SD) 66 (11) 66 (13) 63 (13) 64 (9) .640
Chi2
Gender n % n % n % n % .680
Male 14 67 13 65 18 75 14 58
Tumour localization .303
Lip 0 0 0 0 0 0 2 100
Oral cavity 8 38 11 55 17 71 9 38
Tongue (C01, C02) 3 2 6 1
Gums (C03) 1 3 2 0
Floor of mouth (C04) 3 4 4 6
Oral cavity, unspec. 1 2 5 2
(C00, C05, C06, C14)
Major salivary glands (C07, C08) 1 5 0 0 0 0 0 0
Oropharynx (C09,C10) 2 10 2 10 1 4 4 17
Nasopharynx (C11) 1 5 2 10 1 4 1 4
Nasal Cavity (C30) 0 0 0 1 4 1 4
Hypopharynx (C12, C13) 3 14 1 5 0 0 5 21
Larynx (C32) 6 29 4 20 4 17 2 8
Tumour size .522
T1 9 43 8 40 10 42 4 17
T2 5 24 4 20 5 21 6 26
T3 3 14 2 10 3 13 2 8
T4 4 19 6 30 5 21 12 50
Tx 0 0 0 0 1 0 0 0
In bold main patient characteristics of the dataset (age, gender, tumour localization and size)
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One of the specialist departments tried to reduce
throughput times by creating time slots at the imaging
departments, coded as: ‘Waiting time Radiology or Nu-
clear Medicine (imaging)’.
‘The slots are for radiotherapy patients at the Nuclear
Medicine and Radiology department, for which
hopefully in the future more slots become available in
order to get PET-CT planned earlier. This is a logistic
matter, which means that the amount of patients that
need imaging to fit in the available slots is variable,
sometimes only 2 and sometimes up to 10 patients.
Back then we had less slots available.’
Throughput times reduced again, but because slots at
the imaging department were on consecutive days,
Table 3 Throughput times and hospital visits, pre- and post-MFDC
Pre Post Significance
2007 (n = 21) 2008 (n = 20) 2010 (n = 24) 2013 (n = 24) p ANOVA pair wise comparison
Throughput time (days)
Mean (SD) Mean (SD) Mean (SD) Mean (SD)
Access first consultation 6.0 (7.5*) 5.9 (3.9) 4.9 (3.5) 7.7 (8.0) .592 –
Diagnostic procedures 20.6 (10.6) 11.4 (7.4) 8.7 (5.6) 13.0 (8.0) <.000 2007–2008: .013; 2007–2010: .000; 2007–2013: .049
Start first treatment 32.6 (13.8) 22.2 (9.2*) 23.7 (8.4) 29.3 (11.3) .009 2007–2008: .038
Number hospital visits
Diagnostic procedures 3.0 (1.7) 2.2 (0.7*) 1.7 (0.7) 3.0 (1.3) <.000 2007–2010: .014; 2008–2013: .049; 2010–2013: .001
Diagnosis to start
Treatment
2.1 (1.5) 1.4 (0.9*) 2.4 (1.9) 3.1 (2.2) .032 2008–2013: .012
Total 5.1 (1.7) 3.6 (1.0*) 4.1 (2.1) 6.0 (2.3) <.000 2007–2008: .006; 2008–2013: .000; 2010–2013: .021
Start treatment
within 30 days
52% 83% 71% 54% .132 2007–2008: .040
Legend Table 3. Access first consultation; throughput time from ‘date of the letter of referral’ to ‘intake in oncology front office’, diagnostic procedures; throughput
time from ‘first consultation’ to ‘decision in multidisciplinary meeting of the head & neck cancer centre’, start first treatment; ‘throughput time form first
consultation’ to ‘start first primary treatment’. Hospital visits are measured during the diagnostic procedures, and from diagnosis to start treatment, and in total
*= number of patients is 19, because one patient was treated elsewhere after receiving the diagnostic plan
Fig. 2 Throughput times and hospital visits pre- and post MFDC. Legend Fig. 2. Red line = the Dutch 30-day standard. Darkest grey bar = pre MFDC
situation, year 2007. Dark grey bar = post MFDC situation, year 2008. Lighter grey bar = post MFDC situation, year 2010. Lightest grey bar = post MFDC
situation, year 2013. Hospital visits is shown as hospitals visits from intake to completion of ‘diagnostic procedures’ and as ‘total hospital visits’
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rather than the same day, the number of hospital visits
increased.
– co-morbid patients or patient delay took more time
than expected (in 2013 62% of all patients started
their treatment within the Dutch 30-day standard),
coded as ‘Co-morbid or complex patient’.
‘Madam is admitted to a nursing home and has a
long history – co-morbidity.’
– the interviewees saw opportunities for improvement
of the care pathway, coded as: ‘More attention to
cooperation between disciplines to combine patient
appointments’.
‘Nowadays we do not wait for PEG-placement to start
treatment. During admission for the first chemotherapy,
a PEG-tube can be placed.’
Combining quantitative and qualitative results
Effects of the implementation of the MFDC diminished in
2013 mainly because of the use of newer treatment modal-
ities such as primary radiotherapy and chemo-therapy
(from 32.6 days in 2007 to 22.2 days in 2008, and 23.7 days
in 2010 back to 29.3 days 2013 on average, Table 3). In
some cases patients needed extra time due to personal cir-
cumstances, in other cases preparation of a more complex
treatment took more time and more hospital visits than in
2008 and 2010.
Each specialist gave his or her view on improving man-
agement of the care pathway when asked, they mentioned:
Table 4 Codes in coding tree in relation to the care pathway management
Coding tree Code Code description Frequency
Care pathway Intake Referral 1 Suspicion ‘malignity’ at intake not sufficient 9
Patient related 2 Waiting on family home caregiver 3
3 Co-morbid or complex patient 9
Diagnostic procedures and logistics Throughput time 6 More attention to cooperation between
disciplines to combine patient appointments
6
13 Control/logistics control lies with gate specialist
or ‘core specialist’
6
8 Treatment of dental foci under anaesthesia 2
Waiting time 17 Waiting time Radiology 3
18 Waiting time Nuclear Medicine 2
Treatment and planning Preparation 4 For pre-surgery assessment the treatment
must be known, that is possible when staging
of tumour is ready
3
Choice 14 Choice for treatment on basis of general health
assessment
1
12 Scientific Research increases number of hospital visits 2
Planning 5 Planning reconstruction costs extra time 5
7 Planning capacity operation centre versus
‘examination under anaesthesia’- scopy
5
11 Reconciliation of patient on chemo-radiotherapy 8
Standardizing 16 Unclear starting moment waiting time chemo-
radiotherapy, separate standard ‘Nederlandse
Vereniging voor Radiotherapie en Oncologie’




Transfer 10 Transfer of ‘core specialism’ 1
Information 9 No management information on throughput
times in electronic patient dossier
3
15 No standard patient tracking system 4
Registration 19 Registration information not clear 1
Total quotations 37 76
This coding tree has major and minor themes that were derived from the primary research question (intervention in management of the care pathway) and minor
themes derived during coding
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‘planning that cannot be influenced, when slots are not
available’, ‘access of management information’ and ‘defini-
tions of medical registrations’.
Discussion
We found that throughput times for diagnostic procedures
and start treatment decreased considerably, with about
eight days during the first years after MFDC implementa-
tion in 2007. The reduction in throughput times was a re-
sult of better logistics due to a multidisciplinary diagnostic
plan, made during MFDC. There was no effect on referral
times, because the MFDC is organized once a week. In
2008 the care pathway was in compliance with the Dutch
national standard of 80% of new patients starting their
treatment within 30 calendar-days after oncology intake.
The patients visited the hospital approximately one time
less, during the diagnostic phase. As a consequence of the
introduction of the MFDC, the extra efforts of four special-
ist departments, a special care dentist, a nurse practitioner,
and a coordinating nurse seeing the patient together during
intake, were justified.
However when analysing sustainability through 2010
and 2013 we found that throughput times for diagnostic
procedures were sustainable, but not for start treatment.
Besides that the number of hospital visits for diagnostic
procedures and hospital visits in total increased in 2013
(Table 3). From the outlier-evaluation we learned that
there were four major themes in the coding tree: intake,
diagnostic procedures and logistics, treatment and plan-
ning, and case management for diagnostic procedures and
treatment. Complex treatment and co-morbid patients at
intake took more time. Logistics and planning during the
diagnostic phase were more difficult with complex treat-
ment, more diagnostic or imaging needed to be planned
and treatment with cooperation of different specialist de-
partments were difficult to plan on the same day. Dental
foci treatment can only be performed when the total treat-
ment plan is finished, but slows down the process of plan-
ning for start treatment. New features as 3D-planning for
surgery give better results [21], but increase time to start
treatment. For patients that need the most complex proce-
dures planned, case management for that individual patient,
tracking and tracing for all disciplines, would be helpful to
keep the throughput time at a minimum. In most of these
cases management information was not available and the
involved specialists were not aware that the throughput
times increased. This shows the added value of the MFDC
in reducing the time needed for the diagnostic procedures
for complex care.
In support of the above Ouwens et al. demonstrated in
2007 [22] and 2009 [23] that integrated care for head
and neck cancer patients results in an improvement of
perceived quality of care by improving patient centered-
ness in organizational issues like reducing waiting times
and medical-technical quality of the diagnostic equipment.
According to the guideline, patients need a treatment plan
delivered by a multidisciplinary team of a cancer centre
and an evaluation of the execution of that treatment plan
registered in the patient dossier. To follow those guide-
lines for head and neck cancer it is of utmost importance
for management of cancer centres to have throughput
time and amount of hospital visit information available at
all times [20].
Coordination of the logistics diagnostic procedures is
important to shorten the time until the start of treat-
ment. Time slots for diagnostic procedures can help im-
prove efficiency of the care pathway and start treatment
earlier [10, 24, 25].
We think that in our study we have shown that the
MFDC for head and neck patients is an added value: im-
plementation improved efficiency (reduced throughput
times and hospital visits) and compliance to the Dutch
30-day standard. Therefore, when management of logis-
tics of the care pathway can be trusted for 80% of pa-
tients, specialists can use the multidisciplinary patient
meetings to have collegial discussions on complex cases
and keep focus on patient centeredness.
We decided to include patients in a certain time
period around the intervention to reduce bias. The mo-
ment it was decided that the MFDC would start on a
certain date, changes may occur in procedures and pa-
tient selection. After the implementation of the MFDC
it is likely that there is a learning curve. Therefore we
chose an eight-months period, four months before and
four months after the implementation of the MFDC, in
which no data was gathered.
To evaluate the MFDC implementation we chose
throughput times as process indicators because they are
often regarded as logistic management measures and
used as a ‘benchmark’ for several purposes. Governmen-
tal bodies around the world try to compare their quality
of oncological care with indicators such as necessary in-
frastructure and volume, and throughput time with
other countries [20, 26–30]. However, direct relation be-
tween throughput times and outcome for head and neck
cancer patients in our hospital is not proven. We chose
to follow the Dutch standards that advice to use registra-
tions on new patients with certain malignity only, that we
called ‘with curative intent’. Our indicators for process effi-
ciency (throughput times) were chosen in a framework for
measuring quality by assessing elements of structures or
processes with proven connections with key outcomes of
interest [31–34]. A good quality or process indicator signals
changes in quality and is registered in a reliable manner
[14, 30]. Implementation of structural planning of diagnos-
tic procedures for head and neck cancer patients was found
to have a positive effect on throughput times: time slots as
a logistic structure reduced the diagnostic phase for head
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and neck cancer patients [25]. The structural planning of
slots for diagnostic procedures are appreciated by patient
associations and are reflected in their description of process
indicators [35]. Several studies have shown that clinical
characteristics of patients and prognostic factors explain a
relatively large part of the variation in outcomes, such as
survival and quality of life, while quality-of-care indicators
explain a much smaller part [36–38]. Monitoring the
process of care in a clinical pathway in direct relation to as-
sessment of quality of care is of major importance to
benchmark complex care such as head and neck cancer,
but is difficult to assess [2, 39–41].
We wanted to show with a small sample and a simple
method to evaluate, the effect of an intervention in the
care pathway on efficiency. The added value of the extra
multidisciplinary patient meeting is proven. We think that
the combination of process indicators throughput time
and number of hospital visits can be used in a dashboard
to help care pathway management to monitor and sustain
the agreements made.
The results of this study show that a ‘simple’ interven-
tion, such as the implementation of the MFDC, can im-
prove throughput times directly, which in turn can help
improve the perceived quality of care. Especially with
complex, life-threatening diseases such as head and neck
cancer, shortening of the pathways diagnostic procedure is
important so that treatment can start as early as possible
to give patients a better chance of survival [3, 23, 42, 43].
In case of low-volume, highly complex care such as
head and neck cancer, patients are treated in a centre
with large adherence area, about 11,400 km2 with a total
of 2.3 million inhabitants for our centre. Because of
travel distances, reducing hospital visits with one visit is
a valuable contributor to patient comfort and cost re-
duction. A decrease of time of uncertainty about diagno-
sis, treatment and prognosis also reduces patient anxiety
and increase patient satisfaction [35].
The reduction in throughput time was achieved mainly in
the diagnostic phase of the care pathway. Although this
study did not aim to improve a specific phase before start
treatment, the time between the end of the diagnostic phase
with the treatment plan and the start of the treatment has
become relatively long. We recommend examining produc-
tion agreements or slots for planning with medical support
departments to further reduce the time to start treatment,
thus reducing the risk of upstaging even more.
The reduction in throughput times was a result of bet-
ter logistics due to a multidisciplinary diagnostic plan,
made during MFDC. Management of the care pathway
can use these indicators to stay focused on sustainable,
seamless processes of care in a multidisciplinary setting
[40, 44]. We would like the information needed for care
pathway management to become available through our
electronic patient dossier and in a dashboard, so that
lengthening of throughput times could be detected before
they become unacceptably high. In case of change in
the described process indicator combination from agreed
levels, the management should look for variation or devi-
ation on the agreements on the care pathway (with
best intentions made) that could influence future patient
outcomes.
Conclusions
We showed that the MFDC implementation in the care
pathway had a positive effect on efficiency in the care path-
way. As a consequence, the extra efforts of four specialist
departments, a special care dentist, a nurse practitioner,
and a coordinating nurse seeing the patient together during
intake, were justified. Start treatment times increased as a
result of new treatment modalities that needed more time
for preparation.
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